Evidence map›Paper›PMID 40236692›Full record

ArticleFrontiers in immunology2025

Yuan Tian, Lukas Frischknecht, Fabian Rössler, Thomas Schachtner, Jakob Nilsson

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuan TianDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Lukas FrischknechtDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Fabian RösslerDepartment of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Thomas SchachtnerDivision of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Jakob NilssonDepartment of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antibody-mediated rejection (ABMR) is a major cause of graft loss in kidney transplantation, often associated with Methods: We analyzed 1296 kidney transplant patients to study dnDSA development, its relation to age, gender, and the role of HLA-derived peptide mismatches using the Predicted Indirectly Recognizable HLA Epitopes II (PIRCHE II) score. We categorized dnDSA based on bead reactivity patterns and HLA typing into true, possible, and false dnDSA. Results: During follow-up, 25% of recipients developed dnDSA, 9.3% true, 7.7% possible, and 7.9% false. True dnDSA primarily targeted HLA-DQ (38%), while HLA-C and HLA-DP were uncommon (5% and 3%). Higher PIRCHE II scores were significantly associated with true and possible dnDSA against HLA Class II compared to false dnDSA, supporting our dnDSA classification. For true and possible dnDSA, the single locus PIRCHE II score strongly correlated with locus-specific dnDSA, while the total PIRCHE II score did not appear to influence locus-specific dnDSA development. Younger recipients exhibited a higher risk of dnDSA development, while gender had no impact. Conclusion: Locus-specific PIRCHE II scores are useful in predicting dnDSA risk post-transplantation, particularly in younger recipients. Promoting transplants with low PIRCHE II scores against key HLA loci like HLA-DQ in younger recipients could improve outcomes.

Indexed as

Graft RejectionHLA AntigensIsoantibodiesKidney TransplantationAdultAgedAge FactorsFemaleHistocompatibility TestingHumansMaleMiddle AgedTissue DonorsYoung AdultHLA AntigensIsoantibodiesagedonor specific antibodieskidney transplantationPIRCHEvirtual cross-match

Identifiers

PMID40236692
PMCPMC11997444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.